{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadens antigen presentation.",
      "strength": "strong",
      "evidence": [
        { "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3%", "line_ref": "L28" },
        { "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6%", "line_ref": "L29" }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C02",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with better ICI outcomes in humans.",
      "strength": "tentative",
      "evidence": [
        { "quote": "Retrospective human survival comparison p-value | p=0.01", "line_ref": "L30" },
        { "quote": "Vaccinated subgroup had improved survival under ICI treatment", "line_ref": "L30" }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    },
    {
      "claim_id": "C03",
      "claim": "Type I interferon signaling is required for the sensitization effect.",
      "strength": "strong",
      "evidence": [
        { "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.", "line_ref": "L39" },
        { "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0", "line_ref": "L31" }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C04",
      "claim": "Combination therapy increases immune infiltration.",
      "strength": "strong",
      "evidence": [
        { "quote": "Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x", "line_ref": "L33" },
        { "quote": "Increased immune infiltration with combination therapy", "line_ref": "L33" }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    }
  ]
}